ASYMMETRIC SYNTHESIS OF VANCOMYCIN ANTIBIOTICS

万古霉素类抗生素的不对称合成

• 批准号: 2610695
• 负责人: David A Evans
• 金额: $ 22.69万
• 依托单位: HARVARD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-04-01 至 2002-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2610695
• 关键词: analog; cyclic peptides; cyclization; drug design /synthesis /production; phenolic amine; stereochemistry; vancomycin

The first member of the vancomycin family of peptide antibiotics was isolated in 1956, and the progenitor of the family, vancomycin, has been in clinical use for more than twenty-five years as an antibiotic of last resort. The continuing objective of this research program is to develop efficient approaches to the synthesis of the principal members of the vancomycin family of antibiotics. Accordingly, we will pursue laboratory syntheses of vancomycin and the related congeners eremomycin, ristocetin, teicoplanin, and aridicin A. In conjunction with the execution of these objectives, we will develop new methods for the asymmetric synthesis of complex amino acids and cyclin peptides. In addition, we propose to develop new methodology for the oxidative macrocyclization of phenol-containing peptides to form macrocyclic diphenyl ethers and biphenyls, critical constituents of the vancomycin skeleton. The successful development of this methodology will enable us to pursue a biogenetically modeled synthesis of virtually any member of the vancomycin family. During the course of this project we intend to confirm (correct) the absolute stereochemical assignments of the principal members of this family by total synthesis.

万古霉素肽抗生素家族的第一个成员是